Has the French Medical Equipment Industry valuation changed over the past few years?

Investors are pessimistic on the French Medical Equipment industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 27.7x which is lower than its 3-year average PE of 43.1x. The 3-year average PS ratio of 3.6x is higher than the industry's current PS ratio of 2.2x.

Which industries have driven the changes within the French Healthcare industry?

Investors are most optimistic about the Medical Supplies industry even though it's trading below its 3-year average PE ratio of 43.9x. Analysts are expecting annual earnings growth of 13.0%, which is higher than its past year's earnings growth of 4.7% per year. Investors are most pessimistic about the Medical Equipment industry, which is trading below its 3-year average of 37.6x.

French (CAC) Medical Equipment Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 14 Sep 2026	€76.2b	€34.3b	€2.8b	21.5x	27.7x	2.2x
Wed, 12 Aug 2026	€88.3b	€34.3b	€2.8b	21x	32.1x	2.6x
Fri, 10 Jul 2026	€88.1b	€33.6b	€2.5b	23.7x	35.1x	2.6x
Sun, 07 Jun 2026	€89.2b	€33.6b	€2.5b	23.4x	35.6x	2.7x
Tue, 05 May 2026	€88.9b	€33.6b	€2.5b	22.4x	35.7x	2.6x
Thu, 02 Apr 2026	€101.0b	€33.6b	€2.5b	25x	40.5x	3x
Sat, 28 Feb 2026	€116.6b	€33.7b	€2.6b	27.4x	44.9x	3.5x
Mon, 26 Jan 2026	€135.5b	€32.4b	€2.7b	27.6x	50.9x	4.2x
Wed, 24 Dec 2025	€138.0b	€32.4b	€2.7b	28.3x	51.8x	4.3x
Fri, 21 Nov 2025	€156.5b	€32.4b	€2.7b	30.1x	58.8x	4.8x
Sun, 19 Oct 2025	€157.9b	€32.5b	€2.7b	33.4x	58.7x	4.9x
Tue, 16 Sep 2025	€137.3b	€32.6b	€2.7b	49.4x	51x	4.2x
Thu, 14 Aug 2025	€136.5b	€32.4b	€2.7b	43x	49.7x	4.2x
Sat, 12 Jul 2025	€130.5b	€31.7b	€2.7b	39.4x	47.9x	4.1x
Mon, 09 Jun 2025	€129.8b	€31.7b	€2.7b	38.6x	47.6x	4.1x
Wed, 07 May 2025	€129.1b	€31.7b	€2.7b	32.8x	47x	4.1x
Fri, 04 Apr 2025	€128.2b	€31.7b	€2.8b	33.9x	46.6x	4x
Sun, 02 Mar 2025	€145.5b	€31.5b	€2.7b	35.6x	53.4x	4.6x
Tue, 28 Jan 2025	€130.8b	€30.8b	€2.7b	35.1x	49.2x	4.2x
Thu, 26 Dec 2024	€118.7b	€30.8b	€2.7b	30.1x	44.6x	3.8x
Sat, 23 Nov 2024	€119.6b	€30.8b	€2.7b	29.9x	45x	3.9x
Mon, 21 Oct 2024	€112.3b	€30.8b	€2.7b	30.4x	42.3x	3.6x
Wed, 18 Sep 2024	€107.2b	€30.8b	€2.7b	25.2x	40.4x	3.5x
Fri, 16 Aug 2024	€109.2b	€30.6b	€2.6b	26.2x	41.9x	3.6x
Sun, 14 Jul 2024	€104.9b	€30.2b	€2.6b	26.1x	40.3x	3.5x
Tue, 11 Jun 2024	€107.1b	€30.2b	€2.6b	25.3x	41.3x	3.5x
Thu, 09 May 2024	€104.8b	€30.2b	€2.6b	32.7x	40.7x	3.5x
Sat, 06 Apr 2024	€104.1b	€30.2b	€2.5b	31.4x	41.3x	3.4x
Mon, 04 Mar 2024	€102.3b	€30.2b	€2.5b	31.4x	40.2x	3.4x
Wed, 31 Jan 2024	€95.4b	€30.2b	€2.6b	33x	36.7x	3.2x
Fri, 29 Dec 2023	€94.1b	€30.2b	€2.6b	32.7x	36.2x	3.1x
Sun, 26 Nov 2023	€92.6b	€30.2b	€2.6b	32.2x	35.7x	3.1x
Tue, 24 Oct 2023	€85.8b	€30.2b	€2.6b	29.3x	33.1x	2.8x
Thu, 21 Sep 2023	€91.6b	€30.3b	€2.6b	17.5x	35.4x	3x


FR Market	-1.53%
Healthcare	-1.96%
Medical Equipment	-1.60%
Medical Supplies	-1.43%
Medical Equipment	-2.90%

Company	Last Price	7D	1Y	Valuation
CVX Carvolix	€5.86	1.4% +€4.7m	270.9%	PS385.7x
ALKLH Klea Holding	€0.16	9.7% +€4.4m	-29.2%	PE21.5x
ALSMA S.M.A.I.O	€7.50	1.9% +€788.6k	10.3%	PS4.6x
ALIMP Implanet	€0.17	1.3% +€316.4k	-46.8%	PS2x
ALEMG Laboratoires Euromedis Société anonyme	€5.10	1.0% +€142.8k	22.3%	PS0.4x

Announcement • Jun 10

Intrasense and Guerbet Obtain PMDA Certification In Japan For DUOnco Pancreas AI Software

Intrasense and Guerbet announced that DUOnco Pancreas has obtained PMDA certification in Japan under certification number 308AGBZI00003000 (Class II, Classification: Program 1 Disease Diagnostic Program, Program for X-ray imaging diagnostic device workstations (JMDN code: 40935012)). With this certification, DUOnco Pancreas becomes to our knowledge the first AI software focused on the pancreas to be certified in Japan. Pancreatic cancer remains one of the deadliest malignancies worldwide and represents a particularly important healthcare challenge in Japan. In 2022, 510,992 new cases and 467,409 deaths were estimated worldwide, including 47,627 new cases and 43,265 deaths in Japan. Surgery remains the only potentially curative treatment, but it is generally possible only when the disease is identified at an early stage. Early pancreatic cancer often causes few or no specific symptoms, and lesions can be difficult to identify on CT because of their small size and limited contrast. Because many patients are diagnosed after progression, fewer than 20% are eligible for surgery. Prior studies have also reported that 42% of pancreatic cancers smaller than 2 cm were missed on CT, underlining the need for tools that may help radiologists identify subtle findings earlier. Published data including a recent project led by Guerbet’s research team in collaboration with researchers from the University of Copenhagen, suggest that characteristic CT findings of pancreatic cancers are visible as early as 36 months before diagnosis, indicating an opportunity for earlier detection. DUOnco Pancreas is an AI-based image analysis software designed to assist radiologists in the evaluation of contrast-enhanced CT examinations by highlighting regions of interest in the pancreas. The software is intended to support the detection of regions of interest in the pancreas, the measurement of these areas and the main pancreatic duct maximal size. DUOnco Pancreas is designed to support radiologists in their routine reading workflow. It is not an automated diagnostic system and does not replace physician review, interpretation, or diagnosis. In Japan, Intrasense and Guerbet intend to work closely with local imaging IT partners to integrate DUOnco Pancreas as tightly as possible into radiologists’ existing reading environments, especially through collaboration with PACS vendors and other established system providers. This strategy is intended to provide the best possible user experience by enabling radiologists to access the software within their habitual viewer and routine workflow, while limiting disruption and facilitating adoption in daily practice. This certification in Japan is part of a broader effort by Guerbet and Intrasense to evaluate the clinical value of pancreas-focused AI through research collaborations in Japan and Europe. Among these initiatives is the research collaboration with Kyushu University Hospital, announced by Guerbet in April 2025, to assess the performance of DUOnco Pancreas using a substantial dataset including a majority of Japanese patients and cases of early pancreatic cancer. The certification in Japan builds on the CE marking already obtained in Europe in 2025 for DUOnco Pancreas, which represented a key milestone in the DUOnco roadmap co-developed by Intrasense and Guerbet. The product also received “Breakthrough Device designation” from the FDA in the United States in 2025 which does not represent marketing approval, reflecting its potential to address a global unmet need in medical imaging.

French (CAC) Medical Equipment Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

BIM: Respiratory Volume Risks And New Test Launches Will Shape Outlook

EL: AI Glasses Execution Will Test Premium Multiple And Undervaluation Thesis

New minor risk - Share price stability

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%, EPS upgraded

New minor risk - Market cap size

New minor risk - Share price stability

Consensus EPS estimates fall by 13%

Theraclion Announces Board Changes

High number of new directors

Intrasense and Guerbet Obtain PMDA Certification In Japan For DUOnco Pancreas AI Software

New minor risk - Share price stability

Biosynex SA, Annual General Meeting, Jun 18, 2026